华森制药(002907.SZ)：子公司获得创新药《药物临床试验批准通知书》

Core Viewpoint - Huason Pharmaceutical's subsidiary, Chongqing Huason Yino Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HSN002066C1 tablets, marking a significant milestone in the company's innovative drug development strategy [1] Group 1: Product Development - HSN002066C1 tablets, a selective PARP7 small molecule inhibitor, are developed independently by Huason Yino and possess complete intellectual property rights [1] - The drug is intended for oral administration in the treatment of advanced malignant solid tumors, demonstrating significant tumor suppression activity in various tumor models [1] - HSN002066C1 is the first Class 1 innovative drug project approved for clinical trials by Huason Yino, establishing a solid foundation for the company's strategy of combining innovation and generics [1]